ArticleJournal of neuro-oncology2007
Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.
Article in Journal of neuro-oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- The impact of survivin on prognosis and clinicopathology of glioma patients: a systematic meta-analysis.Molecular neurobiology · 2015Pooled it
- Review
- Increase in serum vimentin levels in patients with glioma and its correlation with prognosis of patients with glioblastoma.Neurosurgical review · 2023Article
- The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines.BMC cancer · 2021Article
- CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity.Oncotarget · 2018Article
- p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.Cellular oncology (Dordrecht, Netherlands) · 2018Article
- Survivin and gliomas: A literature review.Oncology letters · 2016Article
- Expression of p16 and Survivin in gliomas and their correlation with cell proliferation.Oncology letters · 2015Article
- SF002-96-1, a new drimane sesquiterpene lactone from an Aspergillus species, inhibits survivin expression.Beilstein journal of organic chemistry · 2013Article
- Survivin-specific small interfering RNAs enhance sensitivity of glioma U-87MG cells to paclitaxel by promoting apoptosis.Neural regeneration research · 2012Article
- Article
- Lack of prognostic significance of survivin in pediatric medulloblastoma.Pathology oncology research : POR · 2011Article
- RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo.Neuro-oncology · 2011Article
- Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas--an immunohistochemical study.Diagnostic pathology · 2011Article
- Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.Cancer immunology, immunotherapy : CII · 2010Review
- Nuclear survivin expression predicts poorer prognosis in glioblastoma.Journal of neuro-oncology · 2009Article
- Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization.Cancer letters · 2008Article
- Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells.British journal of cancer · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSubcellularly localized (nuclear and/or cytoplasmic) survivin has various functions, and correlates with prognosis of malignant tumors. However, there have been no reports about the significance of subcellularly localized survivin in high-grade astrocytomas. The aim of the present study was to examine the relationship between prognosis and subcellular localization of survivin in high-grade astrocytoma.
methodsWe immunohistochemically examined the pattern of subcellular localization of survivin expression (nuclear, cytoplasmic, or both) in 51 patients with high-grade astrocytoma (19 anaplastic astrocytomas; 32 glioblastomas). We statistically examined the relationship between survivin localization and prognosis, using multivariate analysis including other clinicopathological factors (age, sex, WHO grade, extent of resection, MIB-1 labeling index, and expression of p53 and epidermal growth factor receptor).
resultsAll specimens stained positive for survivin: localized in nucleus only (nuclear-positive group), 10 cases (20%); localized in cytoplasm only (cytoplasmic-positive group), 23 cases (45%); simultaneous expression in nucleus and cytoplasm (nuclear-cytoplasmic group), 19 cases (35%). There was no significant difference in prognosis between the nuclear-positive group and cytoplasmic-positive group (P=0.796). However, the nuclear-cytoplasmic group had significantly shorter overall survival than the nuclear-positive group and the cytoplasmic-positive group (P<0.0001).
conclusionsWe found that simultaneous expression of survivin in both the nucleus and cytoplasm is an important prognostic factor for high-grade astrocytoma. The present findings indicate that subcellular localization of survivin expression is a reliable prognostic factor for patients with this tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.